Data concerning the effectiveness of selected dual-domain antibodies/fusion protein therapeutics

IL-18bp-Fc-IL-1ra in the treatment of Ischemia-Reperfusion Injury and Psoriasis

Ischemia-Reperfusion Protective Effects of IL-18pb-Fc-IL-1ra

^{99m}Tc IL-18bp-Fc-IL-1ra is delivered to ischemia-reperfusion injury site (Autoradiographic imaging vs Evans blue and TTC staining in a rat heart)



Vehicle Control IL-18-Fc-IL-1ra treatment



Infarct determined by TTC staining in rat hearts with ischemia-reperfusion

Conclusion: *By injecting IL-18bp-Fc-IL-1ra before and during the reperfusion procedure you can significantly reduce heart infarct in mice by 3.8 times.*

Effect of TNFR-Fc-IL-1ra and IL-18bp-Fc-IL-1ra Treatment for Psoriasis in Mice



Conclusion: *Both TNFR-Fc-IL-1ra and IL-18bp-Fc-IL-1ra significantly reduces the severity of psoriatic inflammation in K5.TGFβ1^{wt} mice.*

Treatment of Diabesity using a single dual-domain drug

Synergetic Action of Dual-Therapeutic Domain GLP-1 Leptin on Weight Loss in Normal Mice

Body Weight (X±SD)

Day	GLP1-Fc-Leptin	Fc Control	Byetta	Leptin	Fc Control
1	24.7 ± 1.3	23.5 ± 2.7	21.6 ± 2.0	20.9 ± 2.0	21.3 ± 3.7
4	23.7 ± 2.2	23.7 ± 3.0	21.1 ± 2.2	20.7 ± 2.3	21.4 ± 3.3
7	21.9 ± 1.4	23.73 ± 3.2	21.3 ± 2.2	20.1 ± 2.1	22.2 ± 3.9
Mean Weight Change Over 7 Days	**-2.8**	**0.2**	**-0.3**	**-0.8**	**0.9**

Conclusion: *As shown in the table above, GLP-1-Fc-Leptin not only significatnly reduced the weight of mice, but also showed that by fusing GLP1 and Leptin by using a Fc linker, a synergistic effect is created.*

Diabesity - diabetes complicated with obesity or obesity complicated with diabetes

AmProtein's patented combinations of dual-domain drug candiates:
IL-18bp-Fc-IL-1ra
IL-4R-Fc-IL-1ra
TNFRI-Fc-IL-1ra
Symlin-Fc-Leptin
PYY-Fc-Leptin
GLP1-Fc-Leptin

AmProtein Corporation • 355 N. Lantana St. Suite 220 • Camarillo, CA 93010
Tel. (805) 807-3362 • Fax (424) 644-0053 • Email info@amprotein.com for more information.

amProtein